Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Nature Reviews. Rheumatology
|
May 5, 2009
Assessing infection risk with biologic agents in RA: methodological challenges
Mark C Fisher, Jeffrey D Greenberg
Current Reviews in Musculoskeletal Medicine
|
June 29, 2011
Inflammatory bowel disease associated arthropathy
Sheila L Arvikar, Mark C Fisher
The Journal of Rheumatology
|
February 12, 2009
Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity
Mark C Fisher, Bruce N Cronstein
The Annals of Pharmacotherapy
|
March 1, 2013
Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab
Shawn Shetty, Mark C Fisher, A Razzaque Ahmed
Current Rheumatology Reports
|
October 12, 2014
Inpatient gout: a review
Mark C Fisher, Michael H Pillinger, Robert T Keenan
The New England Journal of Medicine
|
October 9, 2014
Case records of the Massachusetts General Hospital. Case 31-2014. A 50-year-old man with back pain, fatigue, weight loss, and knee swelling
Mark C Fisher, John H Stone, William E Palmer
Journal of Wildlife Diseases
|
April 30, 2020
Tissue Residue Levels of the Tranquilizer Combination of Butorphanol, Azaperone, and Medetomidine, and the Antagonists, Naltrexone, Atipamezole, and Tolazoline, in Black Bears (Ursus americanus) Postimmobilization
Lisa L Wolfe, Travis Mays, Mark C Fisher, et al.
Journal of Wildlife Diseases
|
July 18, 2018
EVALUATION OF CHEMICAL IMMOBILIZATION IN CAPTIVE BLACK BEARS ( URSUS AMERICANUS) RECEIVING A COMBINATION OF NALBUPHINE, MEDETOMIDINE, AND AZAPERONE
Lisa L Wolfe, Mary E Wood, Mark C Fisher, et al.
Journal of Wildlife Diseases
|
May 9, 2014
Efficacy of a low-dosage combination of butorphanol, azaperone, and medetomidine (BAM) to immobilize Rocky Mountain elk
Lisa L Wolfe, Mark C Fisher, Tracy R Davis, et al.
Annals of the Rheumatic Diseases
|
May 27, 2017
Response to: 'Is optimizing gout treatment the key to closing the mortality gap in gout patients?' by Brinck <i>et al</i>
Mark C Fisher, Sharan K Rai, Na Lu, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Nature Reviews. Rheumatology
|
May 5, 2009
Assessing infection risk with biologic agents in RA: methodological challenges
Mark C Fisher, Jeffrey D Greenberg
Current Reviews in Musculoskeletal Medicine
|
June 29, 2011
Inflammatory bowel disease associated arthropathy
Sheila L Arvikar, Mark C Fisher
The Journal of Rheumatology
|
February 12, 2009
Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity
Mark C Fisher, Bruce N Cronstein
The Annals of Pharmacotherapy
|
March 1, 2013
Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab
Shawn Shetty, Mark C Fisher, A Razzaque Ahmed
Current Rheumatology Reports
|
October 12, 2014
Inpatient gout: a review
Mark C Fisher, Michael H Pillinger, Robert T Keenan
The New England Journal of Medicine
|
October 9, 2014
Case records of the Massachusetts General Hospital. Case 31-2014. A 50-year-old man with back pain, fatigue, weight loss, and knee swelling
Mark C Fisher, John H Stone, William E Palmer
Journal of Wildlife Diseases
|
April 30, 2020
Tissue Residue Levels of the Tranquilizer Combination of Butorphanol, Azaperone, and Medetomidine, and the Antagonists, Naltrexone, Atipamezole, and Tolazoline, in Black Bears (Ursus americanus) Postimmobilization
Lisa L Wolfe, Travis Mays, Mark C Fisher, et al.
Journal of Wildlife Diseases
|
July 18, 2018
EVALUATION OF CHEMICAL IMMOBILIZATION IN CAPTIVE BLACK BEARS ( URSUS AMERICANUS) RECEIVING A COMBINATION OF NALBUPHINE, MEDETOMIDINE, AND AZAPERONE
Lisa L Wolfe, Mary E Wood, Mark C Fisher, et al.
Journal of Wildlife Diseases
|
May 9, 2014
Efficacy of a low-dosage combination of butorphanol, azaperone, and medetomidine (BAM) to immobilize Rocky Mountain elk
Lisa L Wolfe, Mark C Fisher, Tracy R Davis, et al.
Annals of the Rheumatic Diseases
|
May 27, 2017
Response to: 'Is optimizing gout treatment the key to closing the mortality gap in gout patients?' by Brinck <i>et al</i>
Mark C Fisher, Sharan K Rai, Na Lu, et al.
Page
of 4